The Lancet Oncology Analysis of Cancer Research Cooperation between the United Kingdom and the United States

In recent years, in terms of cancer clinical research, words such as "multinational", "multicenter" and "internationalization" have appeared more and more in our field of vision

The cover features a scale with a globe on each end, a map of North America on the left and a map of Europe on the right

In November 2021, the first UK-US Bilateral Cancer Summit will be held to discuss the major challenges facing cancer research and seek solutions, including: cancer prevention, health inequalities due to social, economic, environmental and other factors, Early diagnosis,

Since 1980, there has been a significant increase in cancer research output in both the UK and the US in terms of publication size

Cancer research co-authored by researchers in the UK and the US has an average annual percentage growth rate of 9.

The UK and the US are quite different in the mode of international cooperation

In addition to the United States, the UK has had significant research collaborations with 8 other countries in the past decade (note: the number of collaborative research in each country accounts for more than 10% of the total), including 6 European countries (Netherlands, Sweden, Spain, France, Italy, Germany), as well as Canada and Australia

Cancer research collaborations in the UK and the US focus on haematological tumours and breast cancer (below)

The UK and the US are more consistent in their focus on basic and exploratory cancer research, pharmacy (eg, marker and systemic therapy research), and epidemiological research

There are also differences in research funding characteristics between the UK and the US

It can also be seen from the data that the United States and the United Kingdom have carried out a lot of cooperation in cancer research, but most collaborative research is limited to drugs and precision medicine

There are still many problems in the field of cancer treatment waiting to be solved

references

Lancet Oncol.